PRA Health Sciences (NASDAQ:PRAH) “Buy” Rating Reiterated Today By Robert W. Baird; The Price Objective is $94.0

March 14, 2018 - By Graig Alexander

 PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences (NASDAQ:PRAH) Rating Reaffirmed

In a note issued to investors and clients on 30 November, The “Buy” rating of PRA Health Sciences (NASDAQ:PRAH) shares was reconfirmed by Robert W. Baird, who now has a $94.0 target price per share on the stock. Robert W. Baird’s target price per share gives a possible upside of 3.64 % from the last stock close of the company.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings Coverage

Among 15 analysts covering PRA Health Sciences (NASDAQ:PRAH), 10 have Buy rating, 0 Sell and 5 Hold. Therefore 67% are positive. PRA Health Sciences has $110.0 highest and $43 lowest target. $92.08’s average target is 1.52% above currents $90.7 stock price. PRA Health Sciences had 42 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) has “Buy” rating given on Monday, March 28 by SunTrust. KeyBanc Capital Markets maintained PRA Health Sciences, Inc. (NASDAQ:PRAH) on Monday, October 16 with “Buy” rating. As per Tuesday, June 21, the company rating was initiated by Credit Suisse. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, August 8. The firm earned “Buy” rating on Monday, February 26 by SunTrust. UBS downgraded the shares of PRAH in report on Tuesday, September 6 to “Neutral” rating. The firm earned “Buy” rating on Thursday, December 14 by MUFG Securities Americas Inc. Credit Suisse reinitiated PRA Health Sciences, Inc. (NASDAQ:PRAH) rating on Friday, August 14. Credit Suisse has “Outperform” rating and $47 target. The firm has “Buy” rating given on Monday, October 30 by SunTrust. The firm has “Buy” rating given on Tuesday, January 30 by KeyBanc Capital Markets.

The stock decreased 1.59% or $1.47 during the last trading session, reaching $90.7. About 389,012 shares traded. PRA Health Sciences, Inc. (NASDAQ:PRAH) has risen 52.22% since March 14, 2017 and is uptrending. It has outperformed by 35.52% the S&P500.

Analysts await PRA Health Sciences, Inc. (NASDAQ:PRAH) to report earnings on April, 24. They expect $0.77 EPS, up 28.33 % or $0.17 from last year’s $0.6 per share. PRAH’s profit will be $49.12M for 29.45 P/E if the $0.77 EPS becomes a reality. After $1.04 actual EPS reported by PRA Health Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.96 % negative EPS growth.

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company has market cap of $5.79 billion. The firm offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It has a 68.71 P/E ratio. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

More recent PRA Health Sciences, Inc. (NASDAQ:PRAH) news were published by: which released: “PRA Health Sciences Named Best CRO in Asia” on March 06, 2018. Also published the news titled: “PRA Health Sciences Receives CRO Leadership Award” on March 14, 2018.‘s news article titled: “Pre-Market Technical Scan on Medical Research Equities — HTG Molecular …” with publication date: March 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.